V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10185705 | 10042679 | 1.76 | 0 | Palliative (P) | 2018-04-01 | 2018-04-22 | LANREOTIDE | 02 | N | CAPECITABINE + CARBOPLATIN | 101518830 |
| 10186892 | 10042682 | 1.68 | 69 | Adjuvant (A) | 2018-06-08 | 2018-06-21 | RCEOP | 02 | N | GEMCARBO | 100272932 |
| 10187101 | 10042684 | 1.63 | 94.4 | Adjuvant (A) | 2019-11-27 | 2019-11-30 | BLEOMYCIN | N | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100147820 |
| 10187561 | 10042687 | 1.62 | 98 | Palliative (P) | 2019-07-06 | 2019-07-13 | ECX | N | null | AVAPRITINIB | 100487904 |
| 10187755 | 10042688 | 1.6 | null | Neo-adjuvant (N) | 2021-05-26 | 2021-05-26 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 02 | N | CHLORAMBUCIL + OFATUMUMAB | 100890940 |
| 10187907 | 10042689 | 1.7 | 87.6 | Disease modification (D) | null | 2019-09-08 | TRASTUZUMAB EMTANSINE | N | N | IDELALISIB + RITUXIMAB | 101610626 |
| 10188203 | 10042690 | 1.77 | null | Disease modification (D) | 2019-10-31 | 2019-11-07 | CAPECITABINE + RT | 02 | N | IRINOTECAN + MDG | 101412489 |
| 10189203 | 10042692 | 1.58 | 81 | null | 2021-04-03 | 2021-04-17 | MPV (cycle 5-9) - maintenance | 02 | null | IRINOTECAN + MDG | 100076185 |
| 10189543 | 10042695 | 1.65 | 0 | Curative (C) | 2018-09-26 | 2018-10-03 | Bevacizumab | N | null | OXALIPLATIN + MDG | 101255944 |
| 10191663 | 10042696 | null | 0 | null | 2022-01-21 | 2022-01-21 | ECX | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101495544 |
| 10191747 | 10042698 | 1.67 | 75 | Palliative (P) | 2019-09-14 | 2019-10-01 | ECF | 02 | N | AZACITIDINE + VENETOCLAX | 100400520 |
| 10192432 | 10042700 | 0 | 82.1 | Palliative (P) | null | 2020-03-05 | Brentuximab Vedotin | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN | 100506525 |
| 10192741 | 10042701 | 1.65 | 63.3 | Palliative (P) | 2019-11-05 | 2019-11-05 | AVELUMAB + AXITINIB | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100290070 |
| 10192845 | 10042702 | 1.69 | 53 | Not known (9) | 2017-04-08 | 2017-04-24 | LANREOTIDE | 2 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100356404 |
| 10193508 | 10042704 | 1.9 | 100.6 | Palliative (P) | 2019-08-10 | 2019-08-10 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 100385003 |
| 10193984 | 10042705 | 1.58 | 82.6 | Palliative (P) | 2018-02-21 | 2018-03-14 | Doxorubicin chemoembolisation | 02 | null | TRASTUZUMAB | 100028567 |
| 10194595 | 10042706 | 1.8 | 47 | null | 2019-09-05 | 2019-09-17 | FLAIR trial | 02 | null | AML19 TRIAL | 100647434 |
| 10195038 | 10042708 | 1.81 | 71.2 | Adjuvant (A) | 2020-01-05 | 2020-01-05 | CETUXIMAB + IRINOTECAN + MDG | null | null | DOXORUBICIN | 100273488 |
| 10195099 | 10042710 | 1.73 | 86.8 | Disease modification (D) | 2016-07-04 | 2016-07-13 | LENVATINIB | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100353327 |
| 10196100 | 10042711 | null | null | null | 2019-08-26 | 2019-08-26 | CHLVPP | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100064424 |
| 10196455 | 10042713 | 1.71 | 100.9 | 03 | 2019-07-09 | 2019-07-16 | IDELALISIB + RITUXIMAB | 02 | N | CHOP | 101072402 |
| 10196748 | 10042715 | 1.83 | 92 | Palliative (P) | 2018-05-14 | 2018-05-29 | TRASTUZUMAB EMTANSINE | 02 | N | BENDAMUSTINE + OFATUMUMAB | 100606505 |
| 10197048 | 10042717 | 1.69 | 60 | null | 2019-09-25 | 2019-10-07 | Bendamustine +/- Prednisolone | 02 | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 100657788 |
| 10197222 | 10042718 | 1.61 | 64.1 | Curative (C) | 2017-04-25 | 2017-04-25 | DABRAFENIB | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 101806166 |
| 10197600 | 10042719 | 1.83 | 74.5 | Palliative (P) | 2021-06-27 | 2021-07-16 | FLAG + Idarubicin | 02 | N | SORAFENIB | 101798709 |
| 10197747 | 10042720 | 1.75 | 104.8 | Palliative (P) | null | 2017-07-24 | Ixazomib + Lenalidomide | N | N | DASATINIB | 100502834 |
| 10197829 | 10042721 | 1.64 | 84.4 | Palliative (P) | 2018-07-18 | 2018-07-18 | Cabazitaxel | 02 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 101814232 |
| 10198234 | 10042723 | 1.9 | 105.8 | Curative (C) | 2019-06-05 | 2022-04-25 | CAPECITABINE + CARBOPLATIN | 02 | null | ABVD | 101679278 |
| 10198505 | 10042725 | 1.67 | 87 | Palliative (P) | 2019-10-09 | 2019-10-15 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | N | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100981226 |
| 10198801 | 10042726 | 1.72 | 0 | Palliative (P) | 2017-07-21 | 2017-07-29 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | N | null | IRINOTECAN + MDG | 101515753 |
| 10200567 | 10042730 | 1.57 | 104 | Palliative (P) | 2016-01-05 | 2016-01-05 | DABRAFENIB | 02 | N | IDELALISIB + RITUXIMAB | 101727357 |
| 10202044 | 10042732 | 1.72 | 62.5 | Palliative (P) | 2018-01-13 | 2018-01-17 | AC | N | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101073860 |
| 10203528 | 10042734 | 1.75 | 88 | Adjuvant (A) | 2017-11-26 | 2017-11-30 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | null | CARBO + FLUOROURACIL | 100896080 |
| 10203945 | 10042736 | 1.72 | null | Adjuvant (A) | null | 2019-04-28 | Obinutuzumab + Venetoclax | 2 | N | IRINOTECAN + MDG | 100600789 |
| 10203955 | 10042737 | 1.74 | 71.2 | Palliative (P) | 2020-01-13 | 2020-01-17 | Vemurafenib | 02 | N | FEC + DOCETAXEL | 101473897 |
| 10208770 | 10042747 | 1.72 | 83 | Curative (C) | 2019-12-04 | 2019-12-04 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | Y | CVD | 101675031 |
| 10208849 | 10042749 | 1.72 | 60.3 | Palliative (P) | 2018-01-12 | 2018-02-19 | ECX | 02 | N | BORTEZOMIB + MELPHALAN | 100114234 |
| 10209795 | 10042751 | 1.69 | 88.8 | Palliative (P) | 2016-09-16 | 2016-09-16 | CARBOPLATIN + GEMCITABINE | 02 | Y | STAMPEDE TRIAL | 100460136 |
| 10209860 | 10042752 | 1.63 | 62.7 | Palliative (P) | 2019-10-15 | 2019-12-19 | CAPECITABINE + MITOMYCIN + RT | 99 | null | FCR | 101658124 |
| 10210083 | 10042753 | 1.69 | 102 | 03 | null | 2020-02-23 | Atezolizumab | null | N | CARDAMON TRIAL | 100979590 |
| 10210860 | 10042755 | null | null | 03 | 2016-12-18 | 2016-12-20 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | null | PACLITAXEL + TRASTUZUMAB | 100412249 |
| 10211631 | 10042757 | null | 57.55 | Palliative (P) | 2017-03-02 | 2017-03-03 | CABOZANTINIB | 02 | null | ATEZOLIZUMAB + BEVACIZUMAB | 100360560 |
| 10212486 | 10042762 | 1.56 | 75.1 | Neo-adjuvant (N) | 2018-07-11 | 2018-07-13 | FLAIR trial | 02 | N | PACLITAXEL + PERTUZUMAB + TRASTUZUMAB | 100371594 |
| 10212602 | 10042763 | 0 | 49.4 | 03 | 2019-10-19 | 2019-11-06 | Cabazitaxel | 02 | N | ABEMACICLIB | 100779482 |
| 10214603 | 10042767 | 1.8 | 85.3 | null | 2019-08-07 | 2019-08-13 | TRASTUZUMAB EMTANSINE | 02 | null | OBINUTUZUMAB + VENETOCLAX | 101175679 |
| 10219474 | 10042770 | 1.49 | 92 | Palliative (P) | 2019-07-14 | 2019-07-14 | SPIRE Trial | 02 | N | BLEOMYCIN | 100206261 |
| 10221009 | 10042773 | 1.65 | 61.6 | Palliative (P) | 2019-01-08 | 2019-02-08 | RCEOP | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100172824 |
| 10221779 | 10042775 | 1.72 | 71 | null | 2019-12-09 | 2019-12-20 | CRIZOTINIB | 02 | null | LANREOTIDE | 101383053 |
| 10222950 | 10042776 | 1.81 | 72.6 | 03 | 2019-01-25 | 2019-02-14 | FCR Oral - Cycle 1 | 02 | Y | ISATUXIMAB + POMALIDOMIDE | 100535154 |
| 10224383 | 10042778 | 1.77 | 102 | Curative (C) | 2012-02-25 | 2018-04-09 | ECX | 02 | N | BORTEZOMIB + DARATUMUMAB | 100665697 |